Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

Proof-of-concept for Use of Transcutaneous Spinal Stimulation (TSS) With the ExaStim® Stimulation System in Adults With Chronic Ischemic Stroke (EXA2611)

29 de outubro de 2026 atualizado por: Casa Colina Hospital and Centers for Healthcare

Proof-of-concept for Use of Transcutaneous Spinal Stimulation (TSS) With the ExaStim® Stimulation System in Chronic Stroke Population

The goal of this clinical trial is to learn about the safety, tolerability, and feasibility of ExaStim transcutaneous electrical stimulation combined with task-specific rehabilitation, and to characterize changes in arm function in adults with chronic unilateral ischemic stroke. The main questions it aims to answer are:

  • Does 12 weeks of ExaStim stimulation combined with structured, task-specific rehabilitation improve arm function?
  • What are the safety, tolerability, and feasibility of ExaStim use in individuals with chronic stroke?

Participants will:

  • Complete a 12-week intervention period combining ExaStim transcutaneous electrical stimulation with structured, task-specific rehabilitation
  • Undergo clinical assessments and outcome testing baseline, week 4, week 8, week 12, and week 17 (follow-up)
  • Monitor and report pain and quality of life via Visual Analog Scales (VAS) and questionnaires throughout the 17-week study duration

Visão geral do estudo

Status

Ainda não está recrutando

Condições

Intervenção / Tratamento

Descrição detalhada

Primary exploratory clinical objective: To characterize change in upper extremity motor impairment following 12 weeks of ExaStim stimulation combined with structured, task-specific rehabilitation in individuals with chronic stroke.

Secondary objective: To characterize safety, tolerability, and feasibility of ExaStim use in individuals with chronic stroke. Exploratory objectives include describing immediate on/off-stimulation differences in dexterity and persistence of observed changes at Week 17; the design is not intended to establish causal effectiveness.

Additional exploratory outcomes:

  • Change from baseline to Weeks 4, 8, and 17 in each of FMA-UE, ARAT, BBT, 9HPT, MAL, and SIS.
  • Change from Week 12 to Week 17 in each of FMA-UE, ARAT, BBT, 9HPT, MAL, and SIS.
  • Descriptive comparison of the group mean FMA-UE change from baseline to Week 12 with the exploratory 4.25-point reference.
  • Change from baseline to Week 12 in Modified Ashworth Scale scores.

The FMA-UE screening range of 20-50 is supported by its use in chronic stroke neuromodulation studies, including VNS-REHAB (Dawson et al., 2021) and the TRICEPS protocol (Baig et al., 2025). This eligibility precedent does not establish a clinically meaningful change threshold for ExaStim. Page, Fulk, and Boyne (2012) reported clinically important differences of 4.25-7.25 points in chronic stroke with mild-to-moderate impairment, depending szon the therapist-rated anchor. Accordingly, 4.25 points will be used only as an exploratory reference when describing observed changes. Group mean change will summarize the overall magnitude of change, while individual changes and baseline scores will show participant variability. Neither a group mean nor an individual change of ≥4.25 points will define study success or a clinically meaningful responder in this proof-of-concept study.

Feasibility will be summarized using screening and enrollment counts, retention through Week 17, completed sessions out of 24 planned, sessions delivering at least 45 minutes of stimulated rehabilitation, actual stimulation minutes, interruptions, and reasons for missed visits or discontinuation. Twice-weekly paired BBT and 9HPT measurements will describe unstimulated trajectories and within-visit changes with stimulation. These summaries supplement the synopsis endpoints without changing their hierarchy. Feasibility measures will be reported descriptively with their denominators; no additional operational success thresholds are specified for this proof-of-concept study.

Tipo de estudo

Intervencional

Inscrição (Estimado)

5

Estágio

  • Não aplicável

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Contato de estudo

Estude backup de contato

Locais de estudo

    • California
      • Pomona, California, Estados Unidos, 91767
        • Casa Colina Hospital and Centers for Healthcare
        • Contato:
        • Contato:
        • Subinvestigador:
          • Emily Rosario, PhD
        • Investigador principal:
          • Yannick Darmon, PT, PhD
        • Subinvestigador:
          • Daniel Humphrey, PT, DPT, NCS

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

18 anos a 75 anos (Adulto, Adulto mais velho)

Aceita Voluntários Saudáveis

Não

Gêneros Elegíveis para o Estudo

Tudo

Descrição

Inclusion Criteria:

  1. Subject must have a documented diagnosis of a singular unilateral ischemic stroke event confirmed by radiology report.
  2. Participant is in the chronic stage of neurological recovery, defined as at least 6 months after the unilateral ischemic stroke event.
  3. Subject is aged 18-75 years
  4. In the investigators or qualified clinician's judgment, the subject must possess sufficient global cognitive capacity to understand and follow study-related instructions, actively participate in task-specific rehabilitation, and provide informed consent. Cognitive capacity will be supported by the subject's ability to follow a three-step command and demonstrate orientation to person, place, time, and situation (4/4)
  5. Subject must have a Fugl-Meyer Assessment-Upper Extremity (FMA-UE) score between 20 and 50 (inclusive) at screening.
  6. Subject must be able to commit to participating in a 17-week study, and be willing to comply with study instructions, agree to make all office and therapy appointments, and complete the entire course of the study
  7. Subject must be deemed medically stable for intensive physical rehabilitation and transcutaneous electrical stimulation, supported by formal written clearance from their primary care physician or managing neurologist.
  8. Subject must be able to understand the study, provide informed consent, and complete the applicable HIPAA authorization using IRB-approved procedures. Literacy alone is not an exclusion. IRB-approved accessible consent methods may be used when needed, while the investigator confirms the participant's own understanding, decision-making capacity, and ability to meet study communication requirements.

Exclusion Criteria:

  1. Active implanted medical device for electrical stimulation
  2. Index stroke is hemorrhagic or involves the brainstem, cerebellum, or thalamus, as confirmed by neuroimaging or medical records.
  3. Other internal metallic objects of unknown or foreign origin (unidentifiable surgical implants, shrapnel, bullet fragments, etc.)
  4. Botox injections to the upper limb(s) in prior 3 months
  5. Severe spasticity, MAS grade >3 (grade 4 only; grade 3 is not excluded by this criterion) in any of the following muscles: shoulder abductors, shoulder flexors, elbow flexors/extensors, wrist flexion, forearm supination or pronation, or finger flexors.
  6. Subject scores <20 or >50 points on the FMA-UE.
  7. BMI > 40.0 (morbid obesity)
  8. Acute medical conditions under active treatment that would contraindicate standard rehabilitation including open wounds, unhealed bone fractures, peripheral neuropathies or painful musculoskeletal dysfunction
  9. Subjects who are pregnant or planned pregnancy during the study. Participants of childbearing potential must agree to effective contraception for the duration of participation.
  10. Allergy to hydrogel, silicone, latex or other product materials
  11. Compromised skin in the area for electrode contact (back of neck and/or hip area)
  12. Uncontrolled cardiopulmonary disease or hypertension
  13. Presence of ongoing dysphagia or aspiration difficulties.
  14. Significant sensory impairments. Subjects who score below a 6 out of 12 on the sensory subscale (section H) of the Fugl Meyer Assessment will be excluded.
  15. Other symptoms that would prohibit use or cause discomfort from stimulation such as hypersensitivity.
  16. History of more than one stroke episode
  17. Severe contractures of upper extremity(s)
  18. Severe receptive and/or expressive aphasia limiting communication and understanding of device and interventions
  19. History of uncontrolled epilepsy or seizures
  20. Unmanaged depression, psychiatric disorders or ongoing substance abuse
  21. Participation in another clinical trial that may interfere with this study

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Finalidade Principal: Viabilidade do dispositivo
  • Alocação: N / D
  • Modelo Intervencional: Atribuição de grupo único
  • Mascaramento: Nenhum (rótulo aberto)

Armas e Intervenções

Grupo de Participantes / Braço
Intervenção / Tratamento
Experimental: ANEUVO ExaStim Stimulation System

Week 0 includes one baseline assessment session and two to three parameter optimization sessions. Participants will attend 2 rehabilitation sessions per week for 12 weeks, for a total of 24 sessions. Each session will provide ~60 minutes of rehabilitation, including at least 45 minutes of active stimulation delivered concurrently with therapeutic activity. The therapist will select activities according to participant goals, affected-arm capacity, movement quality, fatigue, pain, and cardiovascular tolerance. Each session will emphasize repeated practice, functional strength or functional practice. Missed sessions will be rescheduled within the 12-week period if appropriate.

Separate assessment visits occur in Weeks 4, 8, 12, and 17 and may last approximately one to two hours with rest breaks.

The final evaluation is scheduled for Week 17. All assessments will use the same participant-specific baseline date as the time reference, and actual visit dates and intervals will be recorded.

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Fugl-Meyer Assessment for Upper Extremity - Motor Score (FMA-UE)
Prazo: Initial assessment at enrollment, re-assessment at weeks 4, 8, 12, and 17

The Fugl-Meyer Upper Extremity Assessment is a 66-point stroke-specific scale measuring sensorimotor recovery across reflexes, synergies, isolated movements, wrist stability, hand function, and coordination. Each item is scored from 0 to 2 based on performance completeness and compensation. Changes exceeding the minimal clinically important difference (typically 4 to 10 points) reflect meaningful gains in motor control and functional independence.

Initial assessment at enrollment, re-assessment at weeks 4, 8, 12, and 17

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
Action Research Arm Test (ARAT)
Prazo: Initial assessment at enrollment, re-assessment at weeks 4, 8, 12, and 17

The Action Research Arm Test (ARAT) is a 57-point, 19-item observational assessment measuring upper extremity functional capacity and dexterity across grasp, grip, pinch, and gross movement subscales. Each task is scored from 0 to 3 based on completion time, movement quality, and compensation patterns. A score change exceeding the minimal clinically important difference (typically 6 to 10 points) indicates meaningful improvement in real-world arm and hand function.

Initial assessment at enrollment, re-assessment at weeks 4, 8, 12, and 17
Box-and-Blocks Test (BBT)
Prazo: Initial assessment at enrollment, at the start of each treatment session, and during re-assessment visits at weeks 4, 8, 12, and 17

The Box and Block Test measures unilateral gross manual dexterity by recording the number of one-inch wooden blocks a patient can transport over a partition from one compartment to another in 60 seconds. The scoring system simply counts the total number of successfully transferred blocks per hand, with multiple blocks carried simultaneously counting as a single point. An increase in score exceeding the minimal detectable change (typically around 6 or more blocks for stroke populations) indicates a true, statistically significant improvement in hand transport speed and unilateral functional capacity.

Initial assessment at enrollment, at the start of each treatment session, and during re-assessment visits at weeks 4, 8, 12, and 17
9-Hole Peg Test (9HPT)
Prazo: Initial assessment at enrollment, at the start of each treatment session, and during re-assessment visits at weeks 4, 8, 12, and 17

The Nine-Hole Peg Test (9HPT) measures manual dexterity and finger-movement speed by recording the total seconds required for a patient to place and subsequently remove nine pegs into a board. Scoring is based on timing (seconds per trial), where lower times indicate better performance, or converted to "pegs per second" for rate-based analysis. A change in score exceeding the minimal detectable change (typically a reduction of several seconds or roughly 15 to 20% from baseline) indicates a statistically significant improvement in fine motor speed and coordination.

Initial assessment at enrollment, at the start of each treatment session, and during re-assessment visits at weeks 4, 8, 12, and 17
Visual Analog Scale (VAS) for pain
Prazo: Initial assessment at enrollment, at the end of each treatment session, and during re-assessment visits at weeks 4, 8, and 12

The Visual Analog Scale (VAS) measures subjective symptom intensity, such as pain, using a continuous horizontal line anchored by "no symptom" at one end and "worst imaginable symptom" at the other. Patients mark their perceived level, and the score is quantified from 0 to 10, where higher numbers reflect greater symptom severity. A score change exceeding a 2 point change indicates a clinically meaningful improvement or worsening of the patient's symptom experience.

Initial assessment at enrollment, at the end of each treatment session, and during re-assessment visits at weeks 4, 8, and 12

Outras medidas de resultado

Medida de resultado
Descrição da medida
Prazo
Motor Activity Log (MAL)
Prazo: Initial assessment at enrollment, re-assessment at weeks 4, 8, 12, and 17

The Motor Activity Log (MAL) is a structured, semi-structured clinical interview where stroke survivors rate their actual daily arm use in terms of Amount of Use (AOU) and How Well (HW) they perform 30 real-world functional tasks. Each item is scored on a 0-to-5 ordinal scale, ranging from 0 (not used at all) to 5 (used as well as before the stroke), with final scores derived from the average of all items. A change in score exceeding the minimal clinically important difference (typically around 1.0 to 1.1 points for either subscale) indicates a meaningful, real-world translation of laboratory motor gains into spontaneous, daily spontaneous arm use.

Initial assessment at enrollment, re-assessment at weeks 4, 8, 12, and 17
Stroke Impact Scale (SIS)
Prazo: Initial assessment at enrollment, re-assessment at weeks 4, 8, 12, and 17

The Stroke Impact Scale (SIS) is a patient-reported outcome measure evaluating health-related quality of life across eight domains, including strength, hand function, ADLs, mobility, communication, emotion, memory, and participation. Each item is scored on a 1-to-5 ordinal scale, which is then transformed into a standardized 0-to-100 scale per domain, where higher scores reflect better recovery and fewer stroke-related limitations. A score change exceeding the minimal clinically important difference (typically ranging from about 3 to 17 points depending on the specific domain) indicates a statistically reliable and meaningful improvement in the patient's perceived recovery and daily well-being.

Initial assessment at enrollment, re-assessment at weeks 4, 8, 12, and 17
Modified Ashworth Scale (MAS)
Prazo: Initial assessment at enrollment, re-assessment at week 12

Modified Ashworth Scale (MAS), it grades spasticity and muscle hypertonia on a 6-point ordinal scale from 0 (no increase in tone) to 4 (rigid limb in flexion or extension). A decrease in score indicates a reduction in passive resistance and muscle hypertonia, reflecting successful management of spasticity.

Initial assessment at enrollment, re-assessment at week 12

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Patrocinador

Colaboradores

Investigadores

  • Diretor de estudo: Emily Rosario, PhD, Casa Colina Hospital and Centers for Healthcare

Publicações e links úteis

A pessoa responsável por inserir informações sobre o estudo fornece voluntariamente essas publicações. Estes podem ser sobre qualquer coisa relacionada ao estudo.

Publicações Gerais

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Estimado)

18 de novembro de 2026

Conclusão Primária (Estimado)

18 de maio de 2027

Conclusão do estudo (Estimado)

18 de novembro de 2027

Datas de inscrição no estudo

Enviado pela primeira vez

29 de outubro de 2026

Enviado pela primeira vez que atendeu aos critérios de CQ

29 de outubro de 2026

Primeira postagem (Real)

4 de novembro de 2026

Atualizações de registro de estudo

Última Atualização Postada (Real)

4 de novembro de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

29 de outubro de 2026

Última verificação

1 de outubro de 2026

Mais Informações

Termos relacionados a este estudo

Outros números de identificação do estudo

  • StrokeTSS

Plano para dados de participantes individuais (IPD)

Planeja compartilhar dados de participantes individuais (IPD)?

NÃO

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Não

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Sim

produto fabricado e exportado dos EUA

Sim

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .